NEPH Stock Analysis: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$2.87
-0.09 (-3.04%)
▼
5d:
-2.38%
30d:
-24.87%
90d:
-41.19%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NEPH shows positive signals but monitor for confirmation. Market pricing in 8.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NEPH shows positive signals but monitor for confirmation. Market pricing in 8.1% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $2.87, which is considered oversold relative to its 30-day fair value range of $2.97 to $3.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.1) compared to its historical average (28.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NEPH is in a strong downtrend. Immediate support is located at $2.77, while resistance sits at $3.21. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.00 (+143.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NEPH is in a strong downtrend. Immediate support is located at $2.77, while resistance sits at $3.21. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.00 (+143.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.97 -
$3.93
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 143.9% below Wall St target ($7.00)
Fair Price Analysis
30-Day Fair Range
$2.97 -
$3.93
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.77
Resistance Level
$3.21
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.08
Wall Street Target
$7.00
(+143.9%)
Revenue Growth (YoY)
22.2%
Earnings Growth (YoY)
-82.4%
Profit Margin
6.4%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
22.1 vs 28.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$2.64
(-8%)
2-Year Target
$2.42
(-16%)
3-Year Target
$2.23
(-22%)
3-Yr Target (if PE normalizes)
(PE: 22→29)
$2.88
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 116.7%)
$9.69
(+238%)
Base:
(SPY PE: 20.6, Growth: 116.7%)
$9.03
(+215%)
Bear:
(PE: 17.5, Growth: 116.7%)
$7.67
(+167%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Trailing PE: 26.45 | Current EPS (TTM): $0.11
Bull Case
$3.78
(+22%)
Analyst growth 18.2%, PE expands to 29.1
Base Case
$3.44
(+11%)
Market implied 18.2%, PE stable at 26.5
Bear Case
$1.98
(-36%)
Severe decline -20.0%, PE contracts to 22.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.1 to 28.5
Stabilization Target:
$3.70
(+29.1%)
PE Expansion Potential:
+29.1%
Share & Embed Analysis
Last updated: April 02, 2026 11:34 PM ET
Data refreshes hourly during market hours. Next update: 12:34 AM
Data refreshes hourly during market hours. Next update: 12:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$607 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$94 | 61 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 60 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$318 | 61 BUY |
|
AVTR
Avantor Inc |
HOLD
21 analysts |
$11 | 65 BUY |
